Genflow Biosciences PLC (LON: GENF) has submitted a formal request for examination of its patent application in China relating to proprietary SIRT6 variants designed for the treatment of Non-Alcoholic Steatohepatitis
Genflow Biosciences Advances Toward Human Trials for Ageing Therapies
Genflow Biosciences PLC (LSE: GENF, OTCQB: GENFF) has announced progress across its two core research programmes, bringing it closer to initiating human trials for its gene therapies targeting age-related diseases.
ValiRx Plc (AIM: VAL): Ambrose Extends Option on VAL401
Ambrose Healthcare Exercise Option on VAL 401 Out License Agreement for £16 Million plus Royalties
ValiRx PLC (AIM:VAL) Conclusion of Evaluation Project
London, UK – ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health, provides the following update at the conclusion of the Evaluation project from
Genflow Biosciences (LON:GENF) Advancements in SIRT6 Variant Patent Application
Genflow Biosciences Advances SIRT6 Variant Patent Application Following Positive Search Report from European Patent Office
ValiRx PLC (AIM:VAL) Update on proposed sub-license of VAL201
London, UK – ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health announces that, further to the amendment to the Letter of Intent (“LOI”)
ValiRx PLC (AIM:VAL) Update on proposed sub-license of VAL201
Update on proposed sub-license of VAL201
ValiRx PLC (AIM:VAL) Business Update
ValiRx plc (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women’s health, is today pleased to provide an operational update.
ValiRx PLC (AIM:VAL) Agreement to License VAL401 to Ambrose Healthcare
ValiRx Plc (AIM: VAL), a life science company focusing on cancer therapeutics and women’s health, announces that ValiSeek Limited (“ValiSeek”), has entered into an exclusive Option Agreement to license VAL401
ValiRx PLC – Expanded agreement with University of Barcelona
ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health, is today pleased to announce that the evaluation agreement announced on 14 February 2022
Genflow Biosciences implements internal modifications to better align with its objectives in the US
Genflow Biosciences PLC (LSE: GENF), a leading company in the field of longevity, has revealed plans to reorganize its primary board of directors and scientific advisory board (SAB) in order
ValiRx PLC (AIM:VAL) Operational Update
London, UK – ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health, is pleased to announce today the signature of a lease for